Crossmark

Postoperative adjuvant therapy with molecularly targeted agents for non-small cell lung cancer

Published Online: 2024-12-18

Published Print: 2025-02

Authors

Miyoshi, Tomohiro

Tsuboi, Masahiro
License Information

Text and Data Mining valid from 2024-12-18

Version of Record valid from 2024-12-18
More Information

Article History

Received: 28 August 2024

Accepted: 25 November 2024

First Online: 18 December 2024

Declarations

:

: Masahiro Tsuboi has received honoraria from Johnson & Johnson Japan, Medtronic Japan, AstraZeneca KK, Eli Lilly Japan, Chugai Pharmaceutical CO.,LTD, Taiho Pharma, Bristol-Myers Squibb KK, Ono Pharmaceutical CO.,LTD, Novalis, MSD and Daiichi-Sankyo.

Document is current